Karlien S. Moller

Johannesburg, GT, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.

Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.

Journal: JAMA

Published: July 31, 2026

Colonic obstruction secondary to trauma induced intramural haematoma: a rare case report.

Colonic obstruction secondary to trauma induced intramural haematoma: a rare case report.

Journal: South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie

Published: October 07, 2025

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Journal: Nature medicine

Published: June 25, 2025

Pulmonary manifestations of long COVID in Johannesburg, South Africa.

Pulmonary manifestations of long COVID in Johannesburg, South Africa.

Journal: Southern African journal of infectious diseases

Published: March 26, 2025

DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.

DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.

Journal: HIV medicine

Published: May 22, 2024

The long wait for long-acting HIV prevention and treatment formulations.

The long wait for long-acting HIV prevention and treatment formulations.

Journal: The lancet. HIV

Published: March 23, 2024

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.

Journal: The Lancet. Infectious diseases

Published: March 17, 2024

Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.

Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.

Journal: Open forum infectious diseases

Published: August 05, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026